Vaxcyte (PCVX) Shares Outstanding (Weighted Average) (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $139.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $139.5 million, up 2.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $139.5 million (up 2.81% YoY), and the FY2025 annual result was $136.1 million, up 11.55% from the prior year.
• Shares Outstanding (Weighted Average) improved to $139.5 million in Q1 2026 per PCVX's latest filing, from $136.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $139.5 million in Q1 2026 and troughed at $57.5 million in Q1 2022.
• A 5-year average of $104.4 million and a median of $111.7 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) surged 64.01% in 2023, then advanced 2.81% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $64.9 million in 2022, then soared by 49.75% to $97.2 million in 2023, then climbed by 25.57% to $122.0 million in 2024, then climbed by 11.55% to $136.1 million in 2025, then grew by 2.51% to $139.5 million in 2026.
• Business Quant data shows PCVX's Shares Outstanding (Weighted Average) at $139.5 million in Q1 2026, $136.1 million in Q4 2025, and $136.2 million in Q3 2025.